<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075608</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000347379</org_study_id>
    <secondary_id>H-22603</secondary_id>
    <nct_id>NCT00075608</nct_id>
  </id_info>
  <brief_title>2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis</brief_title>
  <official_title>Phase II Trial of Second Autologous Transplantation in AL Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma
      cells, either by killing the cells or by stopping them from dividing. Having a stem cell
      transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses
      of chemotherapy to be given so that more plasma cells are killed. By reducing the number of
      plasma cells, the disease may progress more slowly.

      PURPOSE: This phase II trial is studying how well autologous stem cell transplant works in
      treating patients with persistent or recurrent primary systemic (AL) amyloidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the feasibility and tolerability of second autologous stem cell
           transplantation in patients with persistent or recurrent AL amyloidosis.

        -  Determine the response rate and durability of response in patients treated with this
           regimen.

        -  Determine immune reconstitution in patients treated with this regimen.

      OUTLINE:

        -  Mobilization: Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily
           beginning before the initiation of stem cell collection and continuing until the day
           before the completion of stem cell collection.

        -  Preparative regimen: Patients receive high-dose melphalan IV over 20 minutes on days -3
           and -2.

        -  Autologous stem cell transplantation: Autologous stem cells are reinfused on day 0.

      Patients are followed at 6 months, 1 year, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 19 patients will be accrued for this study within 5-6 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor accrual
  </why_stopped>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and Tolerability</measure>
    <time_frame>3 months after treatment and annually</time_frame>
    <description>Feasibility and tolerability will be evaluated based on participants completing second transplant with tolerable adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response and Durability of Response</measure>
    <time_frame>3 months after treatment and annually</time_frame>
    <description>Response and durability of response will be based on hematologic Complete Response or Partial Response and date of relapse or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Immune Reconstitution</measure>
    <time_frame>3 months after treatment and annually</time_frame>
    <description>Evaluate immune reconstitution based on time to engraftment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>2nd Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mobilization with filgrastim autologous stem cell transplantation with melphalan conditioning stem cell infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection</description>
    <arm_group_label>2nd Stem Cell Transplant</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>140-200 mcg/kg IV over two days</description>
    <arm_group_label>2nd Stem Cell Transplant</arm_group_label>
    <other_name>alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous stem cell transplantation</intervention_name>
    <description>infusion of previously collected stem cells on Day 0</description>
    <arm_group_label>2nd Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stem cell infusion</intervention_name>
    <description>infusion of previously collected stem cells on Day 0</description>
    <arm_group_label>2nd Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed AL amyloidosis

               -  Persistent or recurrent disease after 1 course of prior high-dose chemotherapy

          -  Previously treated with autologous stem cell transplantation

          -  Significant initial improvement in organ function after prior high-dose melphalan,
             defined by at least 1 of the following:

               -  Complete hematologic remission (e.g., absence of monoclonal spike by
                  immunofixation in serum and urine AND less then 5% plasma cells in bone marrow
                  with no clonal predominance) OR partial hematologic response (e.g., any decrease
                  in serum or urine monoclonal protein OR decrease in bone marrow plasmacytosis)

               -  Greater than 50% reduction in proteinuria with preservation of creatinine
                  clearance

               -  Greater than 50% reduction in alkaline phosphatase OR at least 2 cm decrease in
                  liver size by physical exam

               -  Subjective neurologic improvement, as confirmed by neurologist

               -  Cardiac stabilization of disease confirmed by echocardiography defined as less
                  than 2 mm increase in mean wall thickness and/or less than 20 g increase in left
                  ventricular mass

               -  Improvement in performance status* NOTE: *This criteria alone does not constitute
                  significant improvement in organ function

          -  Prior stem cell yield must have been ≥ 2 x 10^6 CD34+ cells/kg

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

        Chemotherapy

          -  See Disease Characteristics

          -  No chemotherapy after first transplantation

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 65

        Performance status

          -  Southwest Oncology Group- 0-2

        Life expectancy

          -  More than 6 months

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  See Disease Characteristics

        Renal

          -  See Disease Characteristics

        Cardiovascular

          -  See Disease Characteristics

          -  Left ventricular ejection fraction ≥ 45% by multiple gated acquisition scan or
             echocardiogram

        Pulmonary

          -  diffusing capacity of lung for carbon monoxide ≥ 50%

        Exclusion Criteria:

          -  No myelodysplastic syndromes

          -  No abnormal bone marrow cytogenetics

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Acceptable toxicity from first transplantation, confirmed by the transplant team

          -  HIV negative

          -  No other concurrent malignancy except treated skin cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Quillen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University Cancer Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <results_first_submitted>August 20, 2014</results_first_submitted>
  <results_first_submitted_qc>December 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2017</results_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>Karen Quillen</investigator_full_name>
    <investigator_title>Medical Director, Blood Bank</investigator_title>
  </responsible_party>
  <keyword>primary systemic amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from March 2003 through July 2008 through the transplant clinic and amyloid clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Second Transplant</title>
          <description>Participants underwent a second treatment with high dose chemotherapy and stem cell transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Second Transplant</title>
          <description>Participants underwent a second treatment with high dose chemotherapy and stem cell transplant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.25" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility and Tolerability</title>
        <description>Feasibility and tolerability will be evaluated based on participants completing second transplant with tolerable adverse events</description>
        <time_frame>3 months after treatment and annually</time_frame>
        <population>No data were collected or analyzed due to study termination</population>
        <group_list>
          <group group_id="O1">
            <title>Second Transplant</title>
            <description>Participants underwent a second treatment with high dose chemotherapy and stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility and Tolerability</title>
          <description>Feasibility and tolerability will be evaluated based on participants completing second transplant with tolerable adverse events</description>
          <population>No data were collected or analyzed due to study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response and Durability of Response</title>
        <description>Response and durability of response will be based on hematologic Complete Response or Partial Response and date of relapse or death</description>
        <time_frame>3 months after treatment and annually</time_frame>
        <population>No data were collected or analyzed due to study termination</population>
        <group_list>
          <group group_id="O1">
            <title>2nd SCT</title>
            <description>Mobilization with filgrastim Second autologous peripheral blood stem cell transplant with melphalan conditioning
filgrastim: 16mcg/kg IV daily beginning three days prior to stem cell collection through last day of SCC
melphalan: 140-200 mcg/kg IV over two days
autologous bone marrow transplantation: infusion of previously collected stem cells on Day 0
peripheral blood stem cell transplantation: infusion of previously collected stem cells on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Response and Durability of Response</title>
          <description>Response and durability of response will be based on hematologic Complete Response or Partial Response and date of relapse or death</description>
          <population>No data were collected or analyzed due to study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluate Immune Reconstitution</title>
        <description>Evaluate immune reconstitution based on time to engraftment</description>
        <time_frame>3 months after treatment and annually</time_frame>
        <population>No data were collected or analyzed due to study termination</population>
        <group_list>
          <group group_id="O1">
            <title>2nd SCT</title>
            <description>Mobilization with filgrastim Second autologous peripheral blood stem cell transplant with melphalan conditioning
filgrastim: 16mcg/kg IV daily beginning three days prior to SCC through last day of SCC
melphalan: 140-200 mcg/kg IV over two days
autologous bone marrow transplantation: infusion of previously collected stem cells on Day 0
peripheral blood stem cell transplantation: infusion of previously collected stem cells on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Immune Reconstitution</title>
          <description>Evaluate immune reconstitution based on time to engraftment</description>
          <population>No data were collected or analyzed due to study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Adverse events were assessed for up to 1 year.</desc>
      <group_list>
        <group group_id="E1">
          <title>Second Transplant</title>
          <description>Participants who received a second transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Grade IV</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <description>Grade III</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>Grade III</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>Grade III</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <description>Grade III and IV</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <description>Grade III and IV</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <description>Grade IV</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Boston Medical Center</organization>
      <phone>617-638-8261</phone>
      <email>sfenness@bu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

